NASDAQ:EYES - Second Sight Medical Products Stock Price, News & Analysis

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Second Sight Medical Products Inc (NASDAQ:EYES) announced its quarterly earnings results on Tuesday, August, 6th. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. The medical device company earned $1.28 million during the quarter, compared to analyst estimates of $0.45 million. Second Sight Medical Products had a negative net margin of 553.01% and a negative return on equity of 248.94%. View Second Sight Medical Products' Earnings History.

Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Second Sight Medical Products.

1 brokers have issued 12 month target prices for Second Sight Medical Products' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Second Sight Medical Products' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 517.3% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.

Headlines about EYES stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Second Sight Medical Products.

Some companies that are related to Second Sight Medical Products include Viewray (VRAY), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), BioSig Technologies (BSGM), Fc Global Realty (FCRE), Edap Tms (EDAP), Soleno Therapeutics (SLNO), Helius Medical Technologies (HSDT), electroCore (ECOR), IRIDEX (IRIX) and Precision Optics (PEYE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), Opko Health (OPK), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), TransEnterix (TRXC), AVEO Pharmaceuticals (AVEO) and Plug Power (PLUG).

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Second Sight Medical Products' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.02%) and BlackRock Inc. (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View Institutional Ownership Trends for Second Sight Medical Products.

EYES stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and BlackRock Inc.. Company insiders that have sold Second Sight Medical Products company stock in the last year include Edward David Randolph, Jonathan Will Mcguire and Stephen D Okland. View Insider Buying and Selling for Second Sight Medical Products.

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EYES stock can currently be purchased for approximately $0.81.

Second Sight Medical Products has a market capitalization of $100.60 million and generates $6.90 million in revenue each year. The medical device company earns $-35,090,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.View Additional Information About Second Sight Medical Products.

The official website for Second Sight Medical Products is http://www.secondsight.com/.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]